VINCENZO PINTO/AFP via Getty Images
- AstraZeneca and the University of Oxford’s coronavirus vaccine trials can continue in the US, The Wall Street Journal reported.
- The late-stage trial had paused September 6 after AstraZeneca reported “suspected serious adverse reaction” in a UK-based participant.
- The UK resumed clinical trials for AstraZeneca and the University of Oxford vaccines in September, and in Japan earlier this month.
- Visit Business Insider’s homepage for more stories.
The US has allowed a major coronavirus vaccine trial to resume.
The Food and Drug Administration has allowed a COVID-19 vaccine trial commissioned by AstraZeneca and the University of Oxford to resume within the US, according to a Wall Street Journal report.
The vaccine trial was halted on September 6 after the company reported “suspected serious adverse reaction” in a UK-based participant, STAT reported.
The FDA plans to require AstraZeneca researchers to tell participants of the suspected adverse reaction, and monitor them for “neurological events,” per the Journal.
The UK resumed clinical trials for AstraZeneca and the University of Oxford vaccines in September, and in Japan, trials resumed earlier this month.
Johnson & Johnson temporarily paused its coronavirus vaccine trial earlier this month after a participant experienced an unexplained illness.
There are currently 193 research efforts to develop a vaccine, The World Health Organization has reported, and the head of the United States' vaccine effort recently told Business Insider's Andrew Dunn he expects Americans to receive shots in mid-2021.
AstraZeneca and the FDA did not immediately respond to Business Insider's requests for comment.